ERISA Ledger · U.S. DOL EBSA Form 5500 (2024)

Translational Drug Development, LLC

Official 2024 U.S. DOL Form 5500 summary for Translational Drug Development, LLC (Td2 401(k) Plan · EIN 46-4150915 · PN 001): $13.49M net assets, 167 active participants, and $61.73 per $10,000 (61.73 bps).

Reported Form 5500 Fee & Service Summary

Plan SponsorTranslational Drug Development, LLC
Filing IdentifierTd2 401(k) Plan · EIN 46-4150915 · PN 001
Plan Category & State401(k) Defined Contribution (AZ)
Asset-Size Peer Cohort$5M-$25M
Plan Net Assets (2024)$13.49M
Active Participants167
Direct Admin Fee Rate$61.73 per $10,000 (61.73 bps)
Cohort Peer Median$37.06 per $10,000 (37.06 bps)
Primary Recordkeeper / ProviderWells Fargo Advisors Financial Advi
Schedule H Line 4a RemittanceSchedule H Line 4a Late Remittance Reported ($580.00, often administrative timing)

Browse all 78,373 plans & Schedule C vendors · Methodology · Meru AI